DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

If you’re looking for a digital SIM card to keep your phone connected, consider these options for work, travel and leisure.

With Twiist already available in Type 1 diabetes, Sequel has made the automated insulin delivery system available for the Type 2 population.

A wearable blood sugar monitor may help people with type 2 diabetes even when they don't need insulin. In a newly published ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

Shelomi Sanders, a college hoops player, shares her view on sports, family competition and kid rankings, and talks about her ...

Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, ...

The twiist Automated Insulin Delivery System is now available for adults with insulin-treated type 2 diabetes.

Hello Health Rounds readers! Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a ...

DexCom (DXCM) stock jumps as peer-reviewed data from a study for the G7 insulin pump in type 2 diabetes boost its Medicare coverage hopes.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal ...